Hepatitis B vaccine meets main goals in late-stage study

Organisation: Position: Deadline Date: Location:

VBI Vaccines has announced that a late-stage study testing its hepatitis B vaccine against GlaxoSmithKline’s Engerix-B met its main goals, reports Reuters Health. The trial administered VBI’s Sci-B-Vac at a 10 microgram dose against a 20 microgram dose of Engerix-B, a vaccine which was first approved in the US in 1989.

The report says hepatitis B, a viral infection that attacks the liver, is spread by contact with the blood or bodily fluids of an infected person. The World Health Organisation estimates 257m people are living with hepatitis B virus infection.

The seroprotection rate in all patients aged 18 and older who received Sci-B-Vac was 91.4% compared with 76.5% for those who received Engerix-B, the company said. Seroprotection rate is a measure of clinical protection provided by the vaccine.

“We remain on track to submit applications for regulatory approvals in the US, Europe, and Canada beginning mid-year 2020,” CEO Jeff Baxter is quoted in the report as saying.

However, the company said the study did not meet a secondary goal of demonstrating two doses of Sci-B-Vac were non-inferior to three doses of Engerix-B in all patients 18 and above.

Sci-B-Vac is also being studied in another late-stage trial, whose results are expected by the year end, the report said.

Reuters Health report

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.